Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
« Previous Article | Table of Contents | Next Article »
Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1604-1609
Published online before print August 1, 2002, doi: 10.1161/01.ATV.0000032034.91020.0A
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
22/10/1604    most recent
01.ATV.0000032034.91020.0Av1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deux, J.-F.
Right arrow Articles by Letourneur, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deux, J.-F.
Right arrow Articles by Letourneur, D.
Related Collections
Right arrow Autonomic, reflex, and neurohumoral control of circulation
Right arrow Glucose intolerance
Right arrow ACE/Angiotension receptors
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1604.)
© 2002 American Heart Association, Inc.

Vascular Biology

Low Molecular Weight Fucoidan Prevents Neointimal Hyperplasia in Rabbit Iliac Artery In-Stent Restenosis Model

Jean-François Deux; Anne Meddahi-Pellé; Alain F. Le Blanche; Laurent J. Feldman; Sylvia Colliec-Jouault; Françoise Brée; Frank Boudghène; Jean-Baptiste Michel; Didier Letourneur

From ERIT-M 0204 INSERM (J.-F.D., F. Boudghène, D.L.), X. Bichat Hospital, University Paris VII and XIII, Paris; the Department of Radiology (J.-F.D., F. Boudghène), Tenon Hospital, Paris; INSERM U460 (A.M.-P., L.J.F., J.-B.M.), X. Bichat Medical School, Paris; the Department of Radiology and Medical Imaging (A.F.L.B.), Charles Foix University Hospital, Ivry/s/Seine; IFREMER (S.C.-J.), LBMM, DRV/VP, Nantes; and the Pharmacology Department (F. Brée), University Paris XII Medical School, Créteil, France.

Correspondence to Didier Letourneur, ERIT-M 0204 INSERM, X. Bichat Hospital, Bat. INSERM 13, 46 rue H. Huchard, 75877 Paris Cedex 18, France. E-mail didier.letourneur{at}galilee.univ-paris13.fr


*    Abstract
up arrowTop
 *Abstract
down arrowIntroduction
 down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Objective— Smooth muscle cell (SMC) proliferation within the intima is regulated by heparan sulfates. We studied a low molecular weight (LMW) fucoidan (sulfated polysaccharide from brown seaweed) on SMC proliferation in vitro and intimal hyperplasia in vivo.

Methods and Results— In vitro study revealed that LMW fucoidan reduces rabbit SMC proliferation and is internalized in SMC perinuclear vesicles. On rabbit iliac arteries perfused in vivo with fluorolabeled LMW fucoidan after angioplasty, the labeling was mainly located on sites of injury. Pharmacokinetic studies showed that LMW fucoidan exhibited in rats an elimination half-life of 56±25 minutes (n=8) after intravenous administration and a constant plasma rate for >=6 hours after intramuscular administration. After stent implantation in their iliac arteries, rabbits were also treated with LMW fucoidan (5 mg/kg IM twice a day). Histomorphometric analysis at day 14 indicated that LMW fucoidan reduced intimal hyperplasia by 59% (1.79±0.4 versus 0.73±0.2 mm2, P<0.0001) and luminal cross-sectional area narrowing by 58% (0.38±0.08 versus 0.16±0.04, P<0.0001). Blood samples showed no anticoagulant activity due to LMW fucoidan.

Conclusions— This natural polysaccharide with high affinity for SMCs and sustained plasma concentration markedly reduced intimal hyperplasia, suggesting its use for the prevention of human in-stent restenosis.


Key Words: fucoidan • hyperplasia • restenosis • stent • vascular smooth muscle cell proliferation


*    Introduction
up arrowTop
 up arrowAbstract
 *Introduction
down arrowMethods
 down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Intimal hyperplasia due to migration and proliferation of smooth muscle cells (SMCs) from the media to the intima is a major component of restenosis after stent implantation.1,2 Polysaccharides constitute a large family of molecules capable of developing molecular interactions with cellular targets within the arterial wall.3 For instance, heparin, a natural sulfated polysaccharide, displays pleiotropic effects independent of the anticoagulant activity, including SMC growth inhibition,4 anti-inflammatory activity,5 and growth factor protection.6

Fucoidan is a sulfated polysaccharide extracted from brown seaweed that reduces rat SMC proliferation in vitro in a more intensive manner than heparin.7 We recently succeeded in producing and characterizing new homogeneous fractions of low molecular weight (LMW) fucoidan with low anticoagulant activity.

The aims of the present study were to investigate the ability of LMW fucoidan to regulate vascular SMCs. For this purpose, we first tested the ability of LMW fucoidan to inhibit rabbit SMC proliferation in vitro. We explored the pharmacokinetics of LMW fucoidan injected in rats and the effect of LMW fucoidan on intimal hyperplasia. The results described below indicate that LMW fucoidan is a strong inhibitor of intimal hyperplasia and may be potentially relevant for the treatment of in-stent restenosis.


*    Methods
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 *Methods
down arrowResults
 down arrowDiscussion
 down arrowReferences
 
Polysaccharides
LMW fucoidan was isolated and hydrolyzed by a radical depolymerization process8 from high molecular weight (HMW) extracts of brown marine algae. The characteristics of LMW fucoidan according to previously reported analytical methods9 are as follows: weight-average molecular mass 8±1 kDa; fucose content 35% (wt/wt); uronic acid content 3% (wt/wt); and sulfate content 34% (wt/wt). The anticoagulant activity in vitro of the LMW fucoidan was measured by an activated partial thromboplastin time (APTT), and the amount of LMW fucoidan required to obtain an APTT of 80 seconds (control 40 seconds) was 25 µg/mL.10 The anticoagulant activity in vivo of LMW fucoidan was measured in rabbits by APTT and prothrombin time after intramuscular injection of 5 mg/kg LMW fucoidan. LMW fucoidan was fluorolabeled with the use of 5-([4,6-dichlorotriazin-2-yl]amino)fluorescein.7,11 LMW heparin (6±2 kDa) was commercially available from Sigma Chemical Co.

Cell Culture
Eagle’s minimum essential medium (MEM) and trypsin-EDTA were purchased from GIBCO. Calf serum was obtained from Eurobio. SMCs were isolated from the abdominal aorta of male New Zealand White rabbits.12 Cells were cultured at 37°C in a humidified atmosphere (5% CO2) in MEM supplemented with 10% serum and 2 mmol/L L-glutamine. Third-passage cultures were used throughout the present study.

Growth Studies
Rabbit SMCs (1.2x104) in MEM containing 10% serum were growth-arrested by placing them in medium with 0.4% serum for 72 hours. Cell growth was followed in MEM+10% serum with or without polysaccharides. Toxicity was evaluated by trypan blue and clonal growth assay as described.7 Thymidine uptake at 24 hours was assessed in quadruplicate wells with 1 µCi per well of 6-[3H]thymidine that was pulse-labeled for 60 minutes. Cells were washed, DNA was precipitated with 10% trichloroacetic acid, and radioactivity was counted. Inhibition of SMC proliferation was assessed at day 3 by cell counting of serum-stimulated SMCs in the absence or presence of LMW fucoidan or LMW heparin.

Confocal Study
SMCs plated at low density on coverslips were incubated at 37°C with fluorescent LMW fucoidan (5 µg/mL) for the indicated times, washed 4 times with PBS containing 0.2% BSA, and fixed in 3.7% formaldehyde solution.7 Cultured SMCs were observed under a confocal microscope (Leica SP; excitation wavelength [{lambda}ex] 488 nm, emission wavelength [{lambda}em] 500 to 590 nm).

Pharmacokinetic Experiments
Animal protocols were approved by the Institutional Animal Care and Use Committee of Faculté Bichat. Adult male Wistar rats (280 to 300 g) were anesthetized with intraperitoneal pentobarbital (0.1 mL/kg). A silicon-tipped polyethylene catheter was inserted into the right jugular vein. The bladder was exteriorized and catheterized. A bolus of 5 mg/kg fluorescent LMW fucoidan was injected (1) intravenously via the jugular vein catheter followed by saline solution to flush the catheter or (2) intramuscularly in the right leg. Blood samples were obtained from the catheter at 0, 15, and 30 minutes and at 1, 2, 4, and 6 hours. Urine was collected via the bladder catheter. Blood was centrifuged, and the serum was obtained. The concentration of fluorescent LMW fucoidan was measured in the plasma and urine by a spectrofluorometer at {lambda}ex and {lambda}em of 489 and 515 nm, respectively.

Pharmacokinetic Analysis
Equation 1 describes the time course of fluorescent LMW fucoidan concentration in the blood according to a 2-compartment open model: equation


where A and B are constants. The parameters were determined using the nonlinear least-squares program Micropharm.13

The elimination half-time period, t1/2ß (ß phase), corresponds to the time taken for the concentration of drug in plasma to decline to half of its original value and was calculated from the parameter ß by Equation 2: equation


The clearance (Cl) is the elimination of the drug in milliliters per minute expressed by Equation 3: equation


where AUC is the area under the curve and was calculated by using the trapezoidal rule by the Micropharm program, and D is the administered dose of LMW fucoidan. The apparent distribution volume is the ratio between the amount of drug in a whole organism and its blood or plasma concentration measured at the same time. Percentage of urinary excretion was calculated from the administered dose and the urinary excreted dose.

Angioplasty and Stenting Protocol
Male New Zealand White rabbits (3.5 to 4 kg) received a standard diet. Animals were anesthetized with intravenous pentobarbital, and the right carotid artery was catheterized with a 5F sheath. A 3.0-mm-diameter 20-mm-long angioplasty balloon catheter was advanced over a standard 0.014-in flexible guidewire in both iliac arteries. The iliac arteries were injured by 3 successive 1-minute inflations at 10 atm with a 1-minute reperfusion phase after each inflation. In some experiments, 1 mL fluorescent LMW fucoidan (5 mg/mL) was locally delivered with a 3-mm annular balloon catheter (Nycomed) in the rabbit iliac artery after angioplasty. After 5 minutes, a segment of damaged iliac artery and an adjacent segment of artery were excised, washed with PBS, and observed under a fluorescent microscope. For the stented animals, a 15-mm-long metallic stent (Helistent-Hexacath, Reuil Malmaison) mounted over the balloon was implanted in both iliac arteries immediately after balloon angioplasty (30-second inflation at 10 atm).14 LMW fucoidan at 5 mg/kg was injected intramuscularly twice a day for 14 days. Five animals (2 stents per animal) were treated with LMW fucoidan for 14 days. Five control animals received saline.

Tissue Harvest and Histology Processing
Fourteen days after stenting, rabbits were killed by pentobarbital overdose. Iliac arteries were perfusion-fixed and impregnated in methacrylate as described.14 Four-micron arterial sections were cut with tungsten carbide knives and stained with hematoxylin-eosin, Masson’s trichrome, or orcein. In each artery, 3 sections were taken: 2 at 2 mm from the distal ends of the stent and 1 in the middle. Cell density in the neointima was observed under a microscope and analyzed (Lucia Software, Nikon) for 10 different sections per group.

Morphometric Analysis
Digital planimetry with the use of a video camera mounted on a microscope analyzed the borders of the external elastic lamina, internal elastic lamina, and vessel lumen. A computer program allowed quantification of the intimal, medial, and luminal areas.14 Intimal growth was estimated by using the intimal area, the luminal area, the ratio of intimal to medial areas, and the ratio of the intimal area to the area bounded by the internal elastic lamina (luminal cross-sectional area narrowing).

Statistical Analysis
Results are expressed as mean±SD. The significance of the differences between groups was analyzed by 1-way ANOVA followed by post hoc tests. Values of P<0.05 were considered significant.


*    Results
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 *Results
down arrowDiscussion
 down arrowReferences
 
LMW Fucoidan Inhibits Rabbit SMC Growth In Vitro
We tested the ability of LMW fucoidan to inhibit rabbit SMC growth in vitro. No cell toxicity was observed even at the highest dose (1000 µg/mL). [3H]Thymidine uptake indicated that SMC DNA synthesis 24 hours after serum stimulation was significantly (P<0.001) inhibited in the presence of LMW fucoidan in a dose-dependent fashion: 28±2%, 52±3%, and 78±2% inhibition at 10, 100, and 1000 µg/mL, respectively. LMW heparin was less potent on the inhibition of DNA synthesis with 21±2%, 31±4%, and 49±3% inhibition at 10, 100, and 1000 µg/mL, respectively. By cell counting at day 3, we found that LMW fucoidan was a better SMC growth inhibitor than LMW heparin (Figure 1).



View larger version (20K):
[in this window]
[in a new window]
  		Figure 1. Growth inhibition vs polysaccharide concentration. Rabbit SMCs were released from the growth-arrested phase by addition of culture medium plus 10% serum in the presence of indicated concentrations of LMW fucoidan (•) or LMW heparin ({square}. Cell number was measured after 3 days of incubation. Growth inhibition was calculated by the ratio of cells in the presence of polysaccharide to cells in the control condition. Values are mean±SD of 3 experiments. *P<0.05 vs control, **P<0.001 vs control, and ***P<0.0001 vs control.

LMW Fucoidan Is Internalized in Cultured Rabbit SMCs
Because the growth-inhibitory effect of LMW fucoidan could be, at least in part, due to its internalization in SMCs, we first investigated its uptake by SMCs in vitro. The fate of LMW fucoidan added to cultured rabbit SMCs at 37°C was studied by confocal microscopy using 5 µg/mL of fluorescent LMW fucoidan. After incubation of SMCs, LMW fucoidan was internalized by endocytosis in fluorescent vesicles clearly seen at 6 hours (Figure 2A). The number of fluorescent vesicles in the perinuclear region increased at 24 hours, but nuclear internalization was never observed (Figure 2B).



View larger version (13K):
[in this window]
[in a new window]
  		Figure 2. Uptake of fluorolabeled LMW fucoidan in cultured rabbit SMCs. Rabbit SMCs were exposed at 37°C to 5 µg/mL fluorescent LMW fucoidan for 6 hours (A) or 24 hours (B). They were then fixed with formaldehyde and observed by using a fluorescence confocal microscope. Fluorescent endocytotic vesicles were localized in the perinuclear region 6 hours after exposition to fucoidan (A). The number of fluorescent vesicles increased at 24 hours (B), but nuclear internalization was never observed. Original magnification x1250.

LMW Fucoidan Is Found on Injured Segments of Arteries After Balloon Angioplasty
We then investigated whether LMW fucoidan has an affinity for the arterial wall in vivo. A local delivery catheter was used to deliver fluorescent LMW fucoidan in a rabbit iliac artery after angioplasty. By fluorescence microscopy, an intense fluorescence was revealed on the segment damaged by angioplasty, whereas low fluorescence intensity was detected on the adjacent uninjured segment of the artery (data not shown).

A 2-Compartment Pharmacokinetic Model Describes LMW Fucoidan Distribution In Vivo
The serum concentrations of LMW fucoidan after intravenous or intramuscular injection in rats are displayed in Figure 3A and 3B, respectively. After intravenous injection, LMW fucoidan exhibited a biphasic decline with a rapid decrease of plasma concentration 2 hours after injection and a secondary slow linear decrease (Figure 3A). The pharmacokinetic parameters on 8 adults Wistar rats were as follows: clearance 0.88±0.46 mL/min, t1/2ß 56.5±25.0 minutes, and distribution volume 57.6±27.9 mL. Urinary excretion of LMW fucoidan was 33.2±2.1%. After intramuscular injection, plasma concentration of LMW fucoidan remained in the 10-µg/mL range for at least 6 hours (Figure 3B). Pharmacokinetic analysis revealed that a 2-compartment model described best the plasma behavior of LMW fucoidan.



View larger version (13K):
[in this window]
[in a new window]
  		Figure 3. Plasma concentrations of fluorolabeled LMW fucoidan after intravenous (A) or intramuscular (B) injection in rats. Adult male Wistar rats (280 to 300 g) were injected intravenously via the jugular vein catheter or intramuscularly in the right leg with a bolus of 5 mg/kg fluorolabeled LMW fucoidan. Blood samples were collected, and concentration of LMW fucoidan was measured by a spectrofluorometer at {lambda}ex and {lambda}em of 489 and 515 nm, respectively. Data of plasma concentrations are presented as mean±SD (n=8).

LMW Fucoidan Prevents In-Stent Intimal Hyperplasia in Rabbit Iliac Arteries
No rabbit died during the procedures or the 14-day treatment with LMW fucoidan (5 mg/kg IM). Prothrombin time and APTT were not different in blood samples obtained from LMW fucoidan–treated animals versus control animals (data not shown).

In the animal model, angioplasty (3 successive inflations at 10 atm) and stent implantation for 14 days in rabbit iliac arteries increased (P<0.0001) the intimal area of these arteries (1.79±0.43 mm2) compared with arteries in uninjured animals (0.013±0.002 mm2), whereas the medial area was not different (0.48±0.06 mm2 in uninjured group versus 0.39±0.09 mm2 in stented group).

After angioplasty and stent implantation, LMW fucoidan treatment after 14 days (Figure 4) was associated with a thinner (P<0.001) fibrocellular neointima (101±20 µm) compared with control stenting (236±90 µm). Cell density in the intima was not different (P=0.5) between the 2 groups of stented animals, but the significant decrease of the size of the intima by fucoidan treatment suggested an important limitation of the total number of invading and proliferating SMCs. Morphometric analyses indicated that arterial cross-sectional area was similar in the 2 groups, indicating that stent-induced arterial injury was of similar magnitude in the 2 groups without adverse effect of LMW fucoidan on media integrity (Table). Interestingly, intimal area with LMW fucoidan was significantly (P<0.0001) reduced by 59±11%, the intima/media ratio was reduced by 56±12%, and luminal cross-sectional area narrowing was reduced by 58±10% (Table). In turn, the luminal area of arteries from LMW fucoidan–treated animals was increased (Table, Figure 4).



View larger version (103K):
[in this window]
[in a new window]
  		Figure 4. Representative photomicrographs of rabbit iliac arteries 14 days after angioplasty and stenting in control group (A and C) and in fucoidan-treated group (B and D). a indicates adventitia; i, intima, l, lumen; m, media; s, stent; and {leftrightarrow}, intimal thickness. Original magnifications x12 (A and B) and x66 (C and D).


View this table:
[in this window]
[in a new window]
  		Table 1. Morphometric Analysis of Rabbit Stented Iliac Arteries After 14 Days


*    Discussion
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 *Discussion
down arrowReferences
 
The results described above indicate that LMW fucoidan is a strong inhibitor of intimal hyperplasia in vivo and may be potentially relevant in the treatment of in-stent restenosis. Fucoidans are a family of L-fucose–containing sulfated polysaccharides extracted from brown seaweed, Ascophyllum nodosum.8 This vegetal polymer shares chemical analogies with heparin, a sulfated polysaccharide of animal origin, but exhibits lower anticoagulant activity.7

Continuous administration of HMW fucoidan (>100 kDa) has been shown to reduce intimal hyperplasia after balloon injury in rats.15 Nevertheless, the requirement for continuous administration limits the use of HMW fucoidan for pharmaceutical and clinical applications. In addition, restenosis was induced in the study of McCaffrey et al15 with angioplasty alone, ie, without stent implantation. Surprisingly, there are no published data on the inhibitory effect of LMW fucoidan on intimal hyperplasia. Thus, we decided to test the efficacy of LMW fucoidan on intimal growth after stenting in the rabbit, a model that is more relevant to modern clinical restenosis than is balloon abrasion of the rat carotid artery. The data presented indicated that LMW fucoidan reduced neointimal hyperplasia by {approx}60% and increased the luminal area by {approx}25%, making this compound one of the most efficient ever tested in experimental restenosis by using a noncontinuous administration regimen.16 In contrast to heparin tested in animal models of balloon angioplasty17,18 and clinical trials,19 HMW fucoidan was already used at high dose (25 mg/kg in mice,20 100 mg/kg in rats,21 and 10 mg/kg per hour in rabbits22) without bleeding. In the present study, the fraction of LMW fucoidan (8 kDa), used in rabbits at low dose (5 mg/kg), exhibited no anticoagulant activity in vivo.

In agreement with previous studies using HMW fucoidan in cultured rat and human SMCs,7,23,24 LMW fucoidan reduced rabbit SMC proliferation in vitro and appeared to be a more antiproliferative agent than LMW heparin. Our confocal microscopy studies show that LMW fucoidan has high affinity for cultured SMCs and is internalized in perinuclear endocytotic vesicles. In a previous study using a 20-kDa fucoidan fraction,7,25 we demonstrated that the antiproliferative effect of fucoidan on rat SMCs was mediated by its binding to membrane sites, probably similar to those that mediate the endocytosis of heparin.12,26 Perinuclear localization of LMW fucoidan suggests an antiproliferative activity via intracellular signaling pathways.23,24 We also observed that after angioplasty and local injection of LMW fucoidan in rabbit iliac arteries, the polysaccharide was located on the injured segment of the artery, whereas a low binding was noticed on the artery without angioplasty. This preferential binding in vivo after injury by angioplasty strongly suggested a favorable location of the LMW fucoidan to inhibit SMC activation and proliferation. McCaffrey et al27 suggested that antiproliferative activity of HMW fucoidan on rat and bovine aortic cultured SMCs was linked to the protection of transforming growth factor-ß1 from proteolytic degradation by plasmin and trypsin. We have previously observed an action of HMW fucoidan on growth factors, such as fibroblast growth factor-1 and fibroblast growth factor-2, leading to an increase in endothelial cell proliferation in vitro28 as well the release of tissue factor pathway inhibitor from cultured human endothelial cells,29 which may be relevant in vivo for LMW fucoidan. In vitro and in vivo signaling pathways for the inhibition of SMC growth and migration by LMW fucoidan remain to be fully characterized.

The antiproliferative effect on SMCs of LMW fucoidan probably does not fully explain its potent inhibitory effect on intimal hyperplasia. At least 4 other features of fucoidan may play a role as well: (1) The 2-compartment model that best described the plasma behavior of LMW fucoidan after intravenous administration suggests a rapid organ or cellular uptake followed by a slow decrease. Heparin is cleared through a combination of a rapid mechanism (via endothelial cells and macrophage) and much slower first-order mechanisms via renal excretion.30 Prolonged high plasma rates of LMW fucoidan after intramuscular administration may also facilitate molecular interactions with membrane receptors present on SMCs, which are in contact with blood after the destruction of the endothelial layer by angioplasty. (2) HMW fucoidan is known to modulate leukocyte activation and adhesion via interaction with selectins.31 Monocyte activation and adhesion are important stimuli in in-stent restenosis.32 It has been demonstrated that anti-inflammatory cytokines and monoclonal antibody targeted against monocyte integrins inhibit monocyte infiltration and reduce in-stent intimal hyperplasia.14 HMW fucoidan reduces in vivo neutrophil adhesion and leukocyte migration.33,34 Our recent data indicate that sulfated polysaccharides, including fucoidan, inhibit the release of proinflammatory cytokines/chemokines by activated monocytes,35 which may be relevant for the inhibition of intimal hyperplasia.36 (3) We and other groups have described that HMW and LMW fucoidans have antithrombotic activities and reduce platelet aggregation, an important stimulus of restenosis.10,29,37 (4) HMW fucoidan increases the mobilization of stem/progenitor cells38 and increases plasma levels of stroma-derived factor 1, a highly potent chemoattractant for leukocytes and stem/progenitor cells.39 Because circulating progenitor cells are involved in reendothelialization of injured arteries,40 a mobilization by LMW fucoidan may result in reduced intimal growth.

In conclusion, we reported in the present study promising results of intimal hyperplasia inhibition with a LMW fucoidan in stented rabbit iliac arteries. The low anticoagulant activity, the favorable safety profile, the potent antiproliferative effect on SMCs, and the potential anti-inflammatory properties of LMW fucoidan make it a promising candidate for prevention of in-stent restenosis either systematically or locally via local delivery catheters or coated stents.41,42


*    Acknowledgments
 
This work was supported by INSERM, the Fondation de l’Avenir (Grant ET0-249), the "Année recherche" from AP-HP to J.-F.D., the Fondation de la Recherche Médicale, and the Fondation Bettencourt (Grant "Coup d’élan 2001").

Received June 12, 2002; accepted July 1, 2002.


*    References
up arrowTop
 up arrowAbstract
 up arrowIntroduction
 up arrowMethods
 up arrowResults
 up arrowDiscussion
 *References
 

  1. Casscells W. Migration of smooth muscle and endothelial cells: critical events in restenosis. Circulation. 1992; 86: 723–739.[Free Full Text]
  2. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty: a study in the normal rabbit and the hypercholesterolemic Yucatan micropig. Circulation. 1994; 89: 2816–2821.[Abstract/Free Full Text]
  3. Blondin C, Bataille I, Letourneur D. Polysaccharides for vascular cell targeting. Crit Rev Ther Drug Carrier Syst. 2000; 17: 327–375.[Medline] [Order article via Infotrieve]
  4. Castellot JJ, Cochran DL, Karnovsky MJ. Effect of heparin on vascular smooth muscle cells, I: cell metabolism. J Cell Physiol. 1985; 124: 21–28.[CrossRef][Medline] [Order article via Infotrieve]
  5. Salek-Ardakani S, Arrand JR, Shaw D, Mackett M. Heparin and heparan sulfate bind interleukin-10 and modulate its activity. Blood. 2000; 96: 1879–1888.[Abstract/Free Full Text]
  6. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, Jaye M, Crumley G, Schlessinger J, Lax I. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell. 1994; 79: 1015–1024.[CrossRef][Medline] [Order article via Infotrieve]
  7. Logeart D, Prigent-Richard S, Jozefonvicz J, Letourneur D. Fucans, sulfated polysaccharides extracted from brown seaweed, inhibit vascular smooth muscle cell proliferation, I: comparison with heparin for antiproliferative activity, binding and internalization. Eur J Cell Biol. 1997; 74: 376–384.[Medline] [Order article via Infotrieve]
  8. Nardella A, Chaubet F, Boisson-Vidal C, Blondin C, Durand P, Jozefonvicz J. Anticoagulant low molecular weight fucans produced by radical process and ion exchange chromatography of high molecular weight fucans extracted from the brown seaweed Ascophyllum nodosum. Carbohydr Res. 1996; 289: 201–208.[CrossRef][Medline] [Order article via Infotrieve]
  9. Chevolot L, Foucault A, Chaubet F, Kervarec N, Sinquin C, Fisher AM, Boisson-Vidal C. Further data on the structure of brown seaweed fucans: relationships with anticoagulant activity. Carbohydr Res. 1999; 319: 154–165.[CrossRef][Medline] [Order article via Infotrieve]
  10. Millet J, Jouault SC, Mauray S, Theveniaux J, Sternberg C, Boisson Vidal C, Fischer AM. Antithrombotic and anticoagulant activities of a low molecular weight fucoidan by the subcutaneous route. Thromb Haemost. 1999; 81: 391–395.[Medline] [Order article via Infotrieve]
  11. Stearns NA, Prigent-Richard S, Letourneur D, Castellot JJ. Synthesis and characterization of highly sensitive heparin probes for detection of heparin-binding proteins. Anal Biochem. 1997; 247: 348–356.[CrossRef][Medline] [Order article via Infotrieve]
  12. Battle T, Arnal JF, Challah M, Michel JB. Selective isolation of rat aortic wall layers and their cell types in culture: application to converting enzyme activity measurement. Tissue Cell. 1994; 26: 943–955.[CrossRef][Medline] [Order article via Infotrieve]
  13. Urien S. MicroPharm-K, a microcomputer interactive program for the analysis and simulation of pharmacokinetic processes. Pharm Res. 1995; 12: 1225–1230.[CrossRef][Medline] [Order article via Infotrieve]
  14. Feldman LJ, Aguirre L, Ziol M, Bridou JP, Nevo N, Michel JB, Steg PG. Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits. Circulation. 2000; 101: 908–916.[Abstract/Free Full Text]
  15. McCaffrey TA, Falcone DJ, Borth W, Brayton CF, Weksler BB. Fucoidan is a non-anticoagulant inhibitor of intimal hyperplasia. Biochem Biophys Res Commun. 1992; 184: 773–781.[CrossRef][Medline] [Order article via Infotrieve]
  16. Bult H. Restenosis. a challenge for pharmacology. Trends Pharmacol Sci. 2000; 21: 274–279.[CrossRef][Medline] [Order article via Infotrieve]
  17. Gimple LW, Gertz SD, Haber HL, Ragosta M, Powers ER, Roberts WC, Sarembock IJ. Effect of chronic subcutaneous or intramural administration of heparin on femoral artery restenosis after balloon angioplasty in hypercholesterolemic rabbits: a quantitative angiographic and histopathological study. Circulation. 1992; 86: 1536–1546.[Abstract/Free Full Text]
  18. Hanke H, Oberhoff M, Hanke S, Hassenstein S, Kamenz J, Schmid KM, Betz E, Karsch KR. Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular-weight heparin. Circulation. 1992; 85: 1548–1556.[Abstract/Free Full Text]
  19. Lablanche JM, McFadden EP, Meneveau N, Lusson JR, Bertrand B, Metzger JP, Legrand V, Grollier G, Macaya C, de Bruyne B, Vahanian A, Grentzinger A, Masquet C, Wolf JE, Tobelem G, Fontecave S, Vacheron A, d’Azemar P, Bertrand ME. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study: Fraxiparine Angioplastie Coronaire Transluminale. Circulation. 1997; 96: 3396–3402.[Abstract/Free Full Text]
  20. Zhang XW, Liu Q, Thorlacius H. Inhibition of selectin function and leukocyte rolling protects against dextran sodium sulfate-induced murine colitis. Scand J Gastroenterol. 2001; 36: 270–275.[Medline] [Order article via Infotrieve]
  21. Bojakowski K, Abramczyk P, Bojakowska M, Zwolinska A, Przybylski J, Gaciong Z. Fucoidan improves the renal blood flow in the early stage of renal ischemia/reperfusion injury in the rat. J Physiol Pharmacol. 2001; 52: 137–143.[Medline] [Order article via Infotrieve]
  22. Shimaoka M, Ikeda M, Iida T, Taenaka N, Yoshiya I, Honda T. Fucoidin, a potent inhibitor of leukocyte rolling, prevents neutrophil influx into phorbol-ester-induced inflammatory sites in rabbit lungs. Am J Respir Crit Care Med. 1996; 153: 307–311.[Abstract]
  23. Religa P, Kazi M, Thyberg J, Gaciong Z, Swedenborg J, Hedin U. Fucoidan inhibits smooth muscle cell proliferation and reduces mitogen-activated protein kinase activity. Eur J Vasc Endovasc Surg. 2000; 20: 419–426.[CrossRef][Medline] [Order article via Infotrieve]
  24. Patel MK, Mulloy B, Gallagher KL, O’Brien L, Hughes AD. The antimitogenic action of the sulfated polysaccharide fucoidan differs from heparin in human vascular smooth muscle cells. Thromb Haemost. 2002; 87: 149–154.[Medline] [Order article via Infotrieve]
  25. Logeart D, Prigent-Richard S, Boisson-Vidal C, Chaubet F, Durand P, Jozefonvicz J, Letourneur D. Fucans, sulfated polysaccharides extracted from brown seaweed, inhibit vascular smooth muscle cell proliferation, II: degradation and molecular weight effect. Eur J Cell Biol. 1997; 74: 385–390.[Medline] [Order article via Infotrieve]
  26. Letourneur D, Caleb BL, Castellot JJ. Heparin binding, internalization, and metabolism in vascular smooth muscle cells, II: degradation and secretion in sensitive and resistant cells. J Cell Physiol. 1995; 165: 687–695.[CrossRef][Medline] [Order article via Infotrieve]
  27. McCaffrey TA, Falcone DJ, Vicente D, Du B, Consigli S, Borth W. Protection of transforming growth factor-beta 1 activity by heparin and fucoidan. J Cell Physiol. 1994; 159: 51–59.[CrossRef][Medline] [Order article via Infotrieve]
  28. Giraux JL, Matou S, Bros A, Tapon-Bretaudiere J, Letourneur D, Fischer AM. Modulation of human endothelial cell proliferation and migration by fucoidan and heparin. Eur J Cell Biol. 1998; 77: 352–359.[Medline] [Order article via Infotrieve]
  29. Giraux JL, Tapon-Bretaudiere J, Matou S, Fischer AM. Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells. Thromb Haemost. 1998; 80: 692–695.[Medline] [Order article via Infotrieve]
  30. Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol. 2001; 21: 1094–1096.[Free Full Text]
  31. Heinzelmann M, Polk HC Jr, Miller FN. Modulation of lipopolysaccharide-induced monocyte activation by heparin-binding protein and fucoidan. Infect Immun. 1998; 66: 5842–5847.[Abstract/Free Full Text]
  32. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits: coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol. 1996; 16: 1312–1318.[Abstract/Free Full Text]
  33. Chauvet P, Bienvenu JG, Theoret JF, Latour JG, Merhi Y. Inhibition of platelet-neutrophil interactions by fucoidan reduces adhesion and vasoconstriction after acute arterial injury by angioplasty in pigs. J Cardiovasc Pharmacol. 1999; 34: 597–603.[CrossRef][Medline] [Order article via Infotrieve]
  34. Linnemann G, Reinhart K, Parade U, Philipp A, Pfister W, Straube E, Karzai W. The effects of inhibiting leukocyte migration with fucoidin in a rat peritonitis model. Intensive Care Med. 2000; 26: 1540–1546.[CrossRef][Medline] [Order article via Infotrieve]
  35. Anastase-Ravion S, Carreno M, Blondin C, Ravion O, Champion J, Chaubet F, Haeffner-Cavaillon N, Letourneur D. Heparin-like polymers modulate proinflammatory cytokine production by lipopolysaccharide-stimulated human monocytes. J Biomed Mater Res. 2002; 60: 375–383.[CrossRef][Medline] [Order article via Infotrieve]
  36. Deux JF, Prigent-Richard S, D’Angelo G, Feldman LJ, Puvion E, Logeart-Avramoglou D, Pelle A, Boudghene FP, Michel JB, Letourneur D. A chemically modified dextran inhibits smooth muscle cell growth in vitro and intimal in stent hyperplasia in vivo. J Vasc Surg. 2002; 35: 973–981.[CrossRef][Medline] [Order article via Infotrieve]
  37. Pereira MS, Mulloy B, Mourao PA. Structure and anticoagulant activity of sulfated fucans: comparison between the regular, repetitive, and linear fucans from echinoderms with the more heterogeneous and branched polymers from brown algae. J Biol Chem. 1999; 274: 7656–7667.[Abstract/Free Full Text]
  38. Frenette PS, Weiss L. Sulfated glycans induce rapid hematopoietic progenitor cell mobilization: evidence for selectin-dependent and independent mechanisms. Blood. 2000; 96: 2460–2468.[Abstract/Free Full Text]
  39. Sweeney EA, Lortat-Jacob H, Priestley GV, Nakamoto B, Papayannopoulou T. Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood. 2002; 99: 44–51.[Abstract/Free Full Text]
  40. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964–967.[Abstract/Free Full Text]
  41. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001; 103: 2289–2295.[Abstract/Free Full Text]
  42. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001; 104: 2007–2011.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 BloodHome page
S. Prasad, D. Lillicrap, A. Labelle, S. Knappe, T. Keller, E. Burnett, S. Powell, and K. W. Johnson
Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A
Blood, January 15, 2008; 111(2): 672 - 679.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
H. Hlawaty, A. San Juan, M.-P. Jacob, R. Vranckx, D. Letourneur, and L. J. Feldman
Inhibition of MMP-2 gene expression with small interfering RNA in rabbit vascular smooth muscle cells
Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3593 - H3601.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. C. Lake, R. Vassy, M. Di Benedetto, D. Lavigne, C. Le Visage, G. Y. Perret, and D. Letourneur
Low Molecular Weight Fucoidan Increases VEGF165-induced Endothelial Cell Migration by Enhancing VEGF165 Binding to VEGFR-2 and NRP1
J. Biol. Chem., December 8, 2006; 281(49): 37844 - 37852.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C.-E. Luyt, A. Meddahi-Pelle, B. Ho-Tin-Noe, S. Colliec-Jouault, J. Guezennec, L. Louedec, H. Prats, M.-P. Jacob, M. Osborne-Pellegrin, D. Letourneur, et al.
Low-Molecular-Weight Fucoidan Promotes Therapeutic Revascularization in a Rat Model of Critical Hindlimb Ischemia
J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 24 - 30.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
22/10/1604    most recent
01.ATV.0000032034.91020.0Av1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deux, J.-F.
Right arrow Articles by Letourneur, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deux, J.-F.
Right arrow Articles by Letourneur, D.
Related Collections
Right arrow Autonomic, reflex, and neurohumoral control of circulation
Right arrow Glucose intolerance
Right arrow ACE/Angiotension receptors

ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.